View Activities

CPD 4: Medications Used to Treat Opiate Use Disorder​

Activity Details
  • Credit Amounts:
    • CME: 1.25
    • CPE: 1.25
    • Other: 1.25
    • ASWB ACE: 1.25
    • CNE: 1.25
  • Cost: Free
  • Release: Jan 17, 2024
  • Expires: Jan 17, 2027
  • Estimated Time to Complete:
    1 Hour(s)  15 Minutes
  • Average User Rating:
    (5 Ratings)


Melanie Dicks Melanie Dicks, PharmD
Clinical Assistant Professor, Pharmacy Practice and Science
University of Kentucky College of Pharmacy
Lexington, Kentucky

Needs Statement

Substance use disorder (OUD) is a treatable, chronic disease that often involves cycles of relapse and remission. Individuals who are under the influence of these substances often engage in risky and compulsive behaviors that result in harm to themselves or others. Medication-assisted treatment (MAT) has been proven to successfully treat OUD through various mechanisms including, reducing or eliminating withdrawal symptoms, blunting or blocking the euphoric effects of illicit opioids, relieving cravings, and normalizing brain chemistry and body functions without having the negative effects of the illicit substance. Despite its effectiveness, MAT is not widely used by providers to treat patients with OUD. A major reason for this is that many health professionals are not properly trained in using MAT. There is also a misconception that using MAT is simply substituting one drug for another. This activity describes the mechanisms and effects of different drugs used to treat opioid use disorder and the prescribing of these medications.

Target Audience

Healthcare professionals in a primary care setting.


Upon completion of this educational activity, you will be able to:
1. Name 3 medications FDA approved to treat opioid use disorder
2. Discuss these medications affect on the mu-opiate receptor
3. Identify the Mechanism of Action, Administration Routes, Indication and who can prescribe for all 3 medications
4. Demonstrate the process for initiating treatment for Opioid Use Disorder (OUD) with buprenorphine and extended-release naltrexone
5. Develop individualized plans of care for medication-assisted treatment with buprenorphine and extended-release naltrexone including maintenance and possible taper and discontinuation of the medication
6. Identify how to obtain a waiver to prescribe buprenorphine and additional training resources


In support of improving patient care, University of Kentucky HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This enduring material is designated for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

This training has been approved by the KBML as meeting the statutory requirements of HB1. 0521-H1.0-UK12C

IPE Competencies

  • Roles/ Responsibilities
  • Interprofessional Communication

This knowledge-based activity will award 1.25 contact hours (0.125 CEUs) of continuing pharmacy education credit in states that recognize ACPE providers.

UK Healthcare CECentral certifies this activity for 1.25 hours of participation.

As a Jointly Accredited Organization, UK HealthCare CECentral is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. UK HealthCare CECentral maintains responsibility for this course. Social workers completing this course receive 1.25 clinical continuing education credits.

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.25 nursing contact hours.

Faculty Disclosure

All planners, faculty, and others in control of educational content are required to disclose all their financial relationships with ineligible companies within the prior 24 months.  An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if the educational content an individual can control is related to the business lines or products of the ineligible company.

None of the planners, faculty, and others in control of educational content for this educational activity have relevant financial relationship(s) to disclose with ineligible companies.

The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speakers. In some cases, the presentations might include discussion of investigational agents and/or off-label indications for various agents used in clinical practice. Speakers will inform the audience when they are discussing investigational and/or off-label uses.

Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.


The activity was supported by Anthem.